Our state of the art rapid recombinant monoclonal antibody discovery technologies utilize yeast triple-mode system consisting of in vivo antibody maturation, cell surface presentation and secretion. Unlike other in vitro platforms that are limited by reliance on static VH and VL library repertoires, Abzyme’s antibody maturation approach mimics mammalian antibody diversification & affinity maturation processes.
Abzyme uses an advanced triple-mode yeast-based recombinant monoclonal antibody discovery and optimization technology that includes a rapid, inducible, self-diversifying VH and VL library technology that completely replaces time consuming iterative static library based optimization strategies. Accordingly, the Abzyme approach can deliver tool antibodies and full length optimized high affinity human antibodies in very short times. In addition, Abzyme technology is equally well suited to develop other antibody types and formats such as single domain camelid VHH and human VH antibodies, human ScFV, and rabbit monoclonal antibodies.
Abzyme’s technology is based on the scientific understanding of DNA hypermutation, protein expression and secretion mechanisms in yeast. Unique to Abzyme is our patent-pending eukaryotic-based in vitro antibody discovery/optimization triple-mode platform with proprietary self-diversifying libraries (camelid VHH and human VH single domain antibody libraries, human ScFv and Fab libraries), rapid target-directed antibody maturation and FACS-based single cell sorting approach used to identify diagnostically and therapeutically relevant antibodies. The platform comprises all aspects of antibody discovery and development, from antibody library design, antibody maturation, antibody expression to bio-manufacturing. The Abzyme yeast strains have been extensively engineered to enhance antibody maturation via hypermutation and to optimize antibody expression and transport through the secretory pathway for cell surface presentation and secretion into the culture media. Antibody clones are selected by a multi-step approach including FACS to identify antibodies with desired attributes.